Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CNR1 | P21554 | 7/20 | 0.44 |
| ▸ | CNR2 | P34972 | 10/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448009 | 0.88 | SMN1; SMN2 (0.41) | SMN1; SMN2CNR1CNR2CYP1A2CYP2D6 | |
| SCHEMBL13348250 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2CNR1CNR2CYP1A2CYP2D6 | |
| SCHEMBL3448797 | 0.84 | CNR1 (0.37) | SMN1; SMN2CNR1CNR2CYP1A2CYP2D6 | |
| SCHEMBL3449876 | 0.81 | MAPT (0.32) | SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3378730 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2CNR1CNR2CYP1A2CYP2D6 | |
| SCHEMBL3448683 | 0.79 | GAA (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3374281 | 0.78 | BRD4 (0.43) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3447654 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL13348316 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2CNR1CNR2CYP1A2CYP2D6 | |
| SCHEMBL3449125 | 0.74 | BAZ2B (0.39) | CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SMN1; SMN2 3328/4885CNR1 653/4885CNR2 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.